RECCE PHARMACEUTICALS LTD — Interim / Quarterly Report 2017

Oct 30, 2017

+Rule 4.7B

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00. Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

Quarter ended ("current quarter")
September 2017

	Consolidated statement of cash flows	Current quarter$A	Year to date(3 months)$A
1.	Cash flows from operating activities
1.1	Receipts from ATO	-	-
1.2	Payments for
	(a)research and development	(556,754)	(556,754)
	(b)product manufacturing and operating costs	-	-
	(c)advertising and marketing	-	-
	(d)leased assets	-	-
	(e)staff costs	(155,713)	(155,713)
	(f)administration and corporate costs	(207,977)	(207,977)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	2,224	2,224
1.5	Interest and other costs of finance paid	(2,351)	(2,351)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	-	-
1.9	Net cash from / (used in) operating activities	(920,571)	(920,571)
2.	Cash flows from investing activities
2.1	Payments to acquire:
	(a)property, plant and equipment	(26,580)	(26,580)
	(b)businesses (see item 10)	-	-
	(c)investments(d)intellectual property	--	--
	(e)other non-current assets	-	-
2.2	Proceeds from disposal of:		-
	(a)property, plant and equipment	-	-
	(b)businesses (see item 10)	-	-
	(c)investments	-	-
	(d)intellectual property	-	-
	(e)other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(26,580)	(26,580)

• See chapter 19 for defined terms

1 September 2016 Page 1

	Consolidated statement of cash flows	Current quarter$A	Year to date(3 months)$A
3.	Cash flows from financing activities
3.1	Proceeds from issues of shares	150,000	150,000
3.2	Proceeds from issue of convertible notes	-	-
3.3	Proceeds from exercise of share options	-	-
3.4	Transaction costs related to issues of shares,convertible notes or options	-	-
3.5	Proceeds from borrowings	35,570	35,570
3.6	Repayment of borrowings	(6,978)	(6,978)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	178,592	178,592
4.	Net increase / (decrease) in cash and cashequivalents for the period
4.1	Cash and cash equivalents at beginning ofquarter/year to date	1,090,438	1,090,438
4.2	Net cash from / (used in) operating activities(item 1.9 above)	(920,571)	(920,571)
4.3	Net cash from / (used in) investing activities(item 2.6 above)	(26,580)	(26,580)
4.4	Net cash from / (used in) financing activities(item 3.10 above)	178,592	178,592
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of quarter	321,879	321,879
5.	Reconciliation of cash and cashequivalentsat the end of the quarter (as shown in theconsolidated statement of cash flows) to the relateditems in the accounts	Current quarter$A	Previous quarter$A
5.1	Bank balances	321,879	1,090,438

5.5	Cash and cash equivalents at end of quarter(should equal item 4.6 above)	321,879	1,090,438
5.4	Other (provide details)	-	-
5.3	Bank overdrafts	-	-
5.2	Call deposits	-	-

6.	Payments to directors of the entity and their associates	Current quarter$A
6.1	Aggregate amount of payments to these parties included in item 1.2	125,651
6.2	Aggregate amount of cash flow from loans to these parties included initem 2.3	Nil
6.3	Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B

	Consolidated statement of cash flows	Current quarter$A	Year to date(3 months)$A
7.	Payments to related entities of the entity and their associates		Current quarter$A
7.1	Aggregate amount of payments to these parties included in item 1.2		Nil
7.2	Aggregate amount of cash flow from loans to these parties included initem 2.3		Nil
7.3	Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

8.	Financing facilities availableAdd notes as necessary for an understanding of the position	Total facility amountat quarter end$A	Amount drawn atquarter end$A
8.1	Loan facilities	Nil	Nil
8.2	Credit standby arrangements	Nil	Nil
8.3	Other (please specify)	Nil	Nil

8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.

9.	Estimated cash outflows for next quarter	$A'000
9.1	Research and development *	(690)
9.2	Product manufacturing and operating costs	-
9.3	Advertising and marketing	-
9.4	PP & E	(155)
9.5	Staff costs	(145)
9.6	Administration and corporate costs	(339)
9.7	Other (provide details if material) – SPP	947
9.8	Other (provide details if material) – Funding from ASOF	300
9.9	Other (provide details if material) – R&D Tax rebate	427
9.10	Total estimated cash flows	345
	* This approximate figure is an estimate of expenditure should all R&D during the period progressand give results according to expected outcomes; therefore these estimates are not reliable

10.	Acquisitions and disposals of business entities(items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1	Name of entity	N/A	N/A
10.2	Place of incorporation or registration	N/A	N/A
10.3	Consideration for acquisition or disposal	N/A	N/A
10.4	Total net assets	N/A	N/A
10.5	Nature of business	N/A	N/A

Compliance statement

• 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
• 2 This statement gives a true and fair view of the matters disclosed.

Sign here: ............................................................ Date: ............................................. (Director/Company Secretary)

31 October 2017

Peter Williams Print name: .........................................................

Notes

• 1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
• 1. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
• 1. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.